Infant Bacterial Therapeutics AB (OSTO:IBT B) Change In Receivables : kr22.28 Mil (TTM As of Mar. 2025)

View and export this data going back to 2016. Start your Free Trial

What is Infant Bacterial Therapeutics AB Change In Receivables?

Infant Bacterial Therapeutics AB's change in receivables for the quarter that ended in Mar. 2025 was kr-0.19 Mil. It means Infant Bacterial Therapeutics AB's Accounts Receivable increased by kr0.19 Mil from Dec. 2024 to Mar. 2025 .

Infant Bacterial Therapeutics AB's change in receivables for the fiscal year that ended in Dec. 2024 was kr5.28 Mil. It means Infant Bacterial Therapeutics AB's Accounts Receivable declined by kr5.28 Mil from Dec. 2023 to Dec. 2024 .

Infant Bacterial Therapeutics AB's Accounts Receivable for the quarter that ended in Mar. 2025 was kr0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Infant Bacterial Therapeutics AB's liquidation value for the three months ended in Mar. 2025 was kr137.37 Mil.

Infant Bacterial Therapeutics AB Change In Receivables Historical Data

The historical data trend for Infant Bacterial Therapeutics AB's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Infant Bacterial Therapeutics AB Change In Receivables Chart

Infant Bacterial Therapeutics AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

-4.61

4.34

7.15

-9.31

5.28

Infant Bacterial Therapeutics AB Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Receivables	Get a 7-Day Free Trial															-17.19	15.12	10.62	-3.27	-0.19

Infant Bacterial Therapeutics AB Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr22.28 Mil.

Infant Bacterial Therapeutics AB (OSTO:IBT B) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Infant Bacterial Therapeutics AB's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Infant Bacterial Therapeutics AB's accounts receivable are only considered to be worth 75% of book value:

Infant Bacterial Therapeutics AB's liquidation value for the quarter that ended in Mar. 2025 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	191.758	-	54.392	+	0.75 * 0	+	0.5 * 0
=	137.37

Infant Bacterial Therapeutics AB Change In Receivables Related Terms

Thank you for viewing the detailed overview of Infant Bacterial Therapeutics AB's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Infant Bacterial Therapeutics AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (OSTO:IBT B) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

9IB:Germany

Address

Bryggargatan 10, Stockholm, SWE, 111 21

Website

https://www.ibtherapeutics.com

Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.

Infant Bacterial Therapeutics AB Headlines

No Headlines